Form 4 for VNDA Vanda Pharmaceuticals Inc.
Accepted 2024-05-21 00:00:00 ET · period of report 2024-05-17 · accession 0000950170-24-063022 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-05-21 | 2024-05-17 | VNDA | Honore Tage | Dir | A - Grant | $0.00 | +20.5K | 64.2K | +47% | $0 |
| D | 2024-05-21 | 2024-05-17 | VNDA | Honore Tage | Dir | A - Grant | $0.00 | +37.6K | 37.6K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-05-17 | A | A | 20,529 | $0.00 | 64,244 | D | — | — | (F1) Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on May 17, 2025, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date. |
| 2 | Derivative | Stock Option (right to buy) | 2024-05-17 | A | A | 37,578 | $0.00 | 37,578 | D | $5.48 · — to 2034-05-16 | 37,578 Common Stock | (F2) This option vests and becomes exercisable with respect to 100% of the option shares on May 17, 2025, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date. |